key: cord-1046093-uj4c2zey
authors: Gerber, Pehuén Pereyra; Duncan, Lidia M; Greenwood, Edward JD; Marelli, Sara; Naamati, Adi; Teixeira-Silva, Ana; Crozier, Thomas WM; Gabaev, Ildar; Zhan, Jun R; Mulroney, Thomas E; Horner, Emily C; Doffinger, Rainer; Willis, Anne E; Thaventhiran, James ED; Protasio, Anna V; Matheson, Nicholas J
title: A protease-activatable luminescent biosensor and reporter cell line for authentic SARS-CoV-2 infection
date: 2021-11-24
journal: bioRxiv
DOI: 10.1101/2021.03.22.435957
sha: 50d8a86282a677bbed6b34dd8e2fde4b231252c0
doc_id: 1046093
cord_uid: uj4c2zey

Efforts to define serological correlates of protection against COVID-19 have been hampered by the lack of a simple, scalable, standardised assay for SARS-CoV-2 infection and antibody neutralisation. Plaque assays remain the gold standard, but are impractical for high-throughput screening. In this study, we show that expression of viral proteases may be used to quantitate infected cells. Our assays exploit the cleavage of specific oligopeptide linkers, leading to the activation of cell-based optical biosensors. First, we characterise these biosensors using recombinant SARS-CoV-2 proteases. Next, we confirm their ability to detect viral protease expression during replication of authentic virus. Finally, we generate reporter cells stably expressing an optimised luciferase-based biosensor, enabling viral infection to be measured within 24 h in a 96- or 384-well plate format, including variants of concern. We have therefore developed a luminescent SARS-CoV-2 reporter cell line, and demonstrated its utility for the relative quantitation of infectious virus and titration of neutralising antibodies. Author summary Techniques for measuring infection with SARS-CoV-2 in the laboratory are laborious and time-consuming, and different laboratories use different approaches. There is therefore no generally agreed way to quantitate neutralising antibodies against SARS-CoV-2, which block infection with the virus and protect people from COVID-19. In this study, we describe a new way to measure SARS-CoV-2 infection, which is much simpler and faster than existing methods. It relies on the production of a specific protease enzyme by the virus, which is able to cleave and activate an engineered protein biosensor in infected cells. This biosensor emits light in the presence of viral infection, and the amount of light released is used as a readout for the amount of infectious SARS-CoV-2 present. The signal is very sensitive, so the number of infected cells required is very small, and the method can be scaled-up to test many samples at once. In particular, we demonstrate how it can be used to detect different variants of SARS-CoV-2, and quantitate neutralising antibodies against these viruses.

to quantitate reporter activation (S2A-B Fig) . All reporters showed an increase in FlipGFP 97 fluorescence, but the magnitude of effect was variable (Fig 1B) . We therefore selected the 98

Opt3c-FlipGFP (Fig 1C, MPro) and PLP2-FlipGFP (Fig 1D, PLPro) biosensors for further 99 evaluation. Similar results were obtained using epifluorescence microscopy (Fig 1E) . 100

To confirm the specificity of these biosensors for their cognate protease, the same co-101 transfection assay was used to measure Opt3c-FlipGFP, PLP2-FlipGFP and TEV-FlipGFP 102 activation in pair-wise combination with MPro, PLPro or TEV protease. In each case, an 103 increase in FlipGFP fluorescence was observed only in the presence of cognate protease (Fig 104 These fluorescent biosensors therefore provide proof-of-concept data confirming that viral 124 protease activity may be used to signal SARS-CoV-2 infection. Nonetheless, the magnitude 125 of effect is markedly reduced compared with over-expression of recombinant viral proteases 126 (compare Fig 2B with Fig 1G) . This likely reflects lower levels of protease expression during 127 viral infection (Fig 2C) . In addition, it is possible that the localisation of proteases and/or 128 presence of other viral proteins and endogenous polyprotein substrates during authentic viral 129 infection reduces their likelihood of encountering reporter molecules. 130

To enzymatically amplify the signal from viral protease activity, we next sought to generate 132 equivalent luciferase-based biosensors. The 30F-GloSensor reporter comprises an inactive, 133 circularly permuted firefly luciferase (FFluc) molecule, in which cleavage of a specific 134 oligopeptide linker is able to restore luminescence [12] . Co-expression with Renilla luciferase 135 (Rluc) from the same vector allows reporter levels and cell viability to be normalised between 136 conditions. We therefore generated 30F-GloSensor constructs with the same sequence-137 specific oligopeptide linkers as our FlipGFP-based reporters, together with the equivalent non-138 cleavable controls. These constructs were co-transfected with/without cognate SARS-CoV-2 139 protease into HEK293T cells, and luminescence analysed after 24 h (Fig 3A) . Normalising for 140 observed a modest yet statistically significant reduction in neutralising activity against the 204 B.1.617.2 (delta) variant of concern (Fig 5D) . virological assays, and screens of candidate antiviral compounds. Luminescent assays may 212 be readily adapted to high-throughput platforms and, whilst the mechanism of reporter 213 activation is different, the range of potential applications is similar to TZM-bl reporter cells for 214

able to regulate whole cell levels of ubiquitylation during viral replication [27] , we suspect that 230

PLPro of SARS-CoV-2 may also be able to readily access a wide variety of cellular proteins, 231 including cytosolic reporters. 232

Unlike reverse-engineered fluorescent or luminescent reporter viruses, our reporter cells are 233 able to detect different clinical SARS-CoV-2 isolates without modification of the viral genome, 234

including emerging variants of concern. Beyond SARS-CoV-2, the PLP2 cleavage sequence 235 is highly conserved in SARS-CoV, and partially conserved in MERS-CoV (S1A Fig). This 236 suggests that the Papain-like proteases of these viruses will also be able to activate 30F-237 PLP2, and we confirmed this in the case of recombinant SARS-CoV PLPro (S1B The following chemical compounds were used in this study: lopinavir (APExBIO, A8204); 245 GC376 (a kind gift from Wayne Vuong, John C. Vederas and M. Joanne Lemieux); remdesivir 246 (APExBIO, B8398); favipiravir (BioVision, 2778-5, a kind gift from Aartjan te Velthuis). 247

The following commercial assays and kits were used in this study: Dual-Glo Luciferase Assay 248 System (Promega, E2920); NEBuilder HiFi DNA Assembly Cloning Kit (NEB, E5520S); 5-249 alpha Competent E. coli (NEB, C2987); Micro BCA Protein Assay Kit (Thermo Fisher, 23235). 250

The following antibodies were used in this study: anti-NSP3 (743 -1072) SARS-CoV-2 (MRC 251 PPU reagents, sheep DA126, 1 st bleed, for immunoblot, 1:500); anti-NSP5 SARS-CoV-2 252 (MRC PPU reagents, sheep DA118, 2 nd bleed, for immunoblot, 1:500); anti-SARS-CoV-2 253 spike [1A9] (Genetex, GTX632604, for microscopy and flow cytometry, 1:500); anti-SARS-CoV-2 nucleocapsid (Novus Biologicals, NB100-56683, for immunoblot, 1:1,000); anti-β-actin-255 HRP (Sigma, A5316, for immunoblot, 1:20,000); anti-mouse Alexa Fluor 647 (AF647) 256 secondary (Jackson ImmunoResearch, #715-605-150, for microscopy and flow cytometry, 257 1:1,000); anti-mouse Alexa Fluor 594 (AF594) secondary (Jackson Immunoresearch, #715-258 585-150, for microscopy, 1:1,000). 259

HEK293T cells (a kind gift from Paul Lehner, authenticated by STR profiling [28, 29] ) and 261

VeroE6 cells (a kind gift from Rupert Beale, authenticated by species-specific PCR (IDEXX 262

BioAnalytics)) were cultured in DMEM supplemented with 10% fetal calf serum (FCS), 100 263 units/ml penicillin, and 0.1 mg/ml streptomycin at 37 C in 5% CO2. All cells were regularly 264 screened and confirmed to be mycoplasma negative (Lonza MycoAlert and IDEXX 265 BioAnalytics). 266

To generate FlipGFP-based reporters, the TEV FlipGFP plasmid PCDNA3-FlipGFP(TEV 269 cleavage seq) T2A mCherry (Addgene, #124429, a gift from Xiaokun Shu [9]) was used as a 270 template for pairs of PCR reactions including primers designed to generate overlapping 271 products replacing the TEV cleavage site with the indicated cleavage sequence (S9 Table) . 272

For example, to replace the TEV cleavage site with the PLP2 cleavage sequence, products 273 generated by PCR reactions including 'Near AfeI'/'PLP2 Rv' and 'PLP2 Fw'/'Near AflII' primer 274 pairs were used. The same plasmid was then digested with AfeI and AflII and assembled with 275 the gel purified PCR products using the HiFi Assembly Master Mix (NEB, E5520). 276

For MPro, we selected a wildtype self-cleavage sequence (SAVLQ/SGF, herein termed WT3c) 277 present between nsp4 and nsp5, and an "optimal" cleavage sequence ( To generate a non-cleavable Opt3c-FlipGFP (MPro) reporter, the critical glutamine residue in 282 the cleavage site was changed to isoleucine (TVRLI/SGF). For the PLP2-FlipGFP (PLPro) 283

reporter, the critical LKGG sequence was scrambled to GLGK (TGLGK/APT). 284

To generate circularly permuted firefly luciferase (FFluc)-based reporters, the pGloSensor-286 30F plasmid (Promega; discontinued, but available on request) was digested with BamHI and 287

HindIII, then assembled (as above) with oligonucleotides encoding the indicated cleavage 288 sequences (S10 Table) . 289

To generate a lentiviral expression vector for the 30F-PLP2 reporter (S4 Fig) , the pCMV-290 intron-30F-PLP2-pA-pSV40-hRluc reporter cassette was first amplified from the pGloSensor-291 30F PLP2, then assembled (as above) with pHRSIN-pCMV-EGFP-PGK-Puro [31] digested 292 with EcoRI and NotI. Next, the SV40 poly(A) signal and promoter were replaced with an 293 internal ribosome entry site (IRES) to generate the final pHRSIN-30F-PLP2-IRES-hRluc-294 WPRE-PGK-Puro lentiviral expression vector. In brief, the pA-pSV40-hRluc fragment was 295 excised by digestion with SalI, and replaced by three-way HiFi assembly (as above) with 296 Renilla luciferase amplified by PCR from pGloSensor-30F and a 586 bp encephalomyocarditis 297 virus (EMCV) IRES. The final sequence of the 30F-PLP2-IRES-hRluc-WPRE-PGK-Puro 298 reporter cassette is shown (S11 Appendix). 299

To generate an expression vector for SARS- In brief, images were acquired using a Cellomics ArrayScan XTI high-throughput imaging 409 platform (Thermo Fisher) using a 386 nm excitation/emission filter to detect DAPI-stained 410 nuclei and a 560 nm excitation/emission filter to detect AF594. Images were then analysed 411 with built-in high content HCS Studio software (by Thermo Fisher) using the Target Activation 412 application. For this, cellular objects were identified by applying overlays (masks) based on 413 DAPI intensity. Necessary steps to exclude non-cellular artefacts (large or small objects) were 414 activated based on average nuclei size. Additionally, background correction was performed 415 on both channels. The generated nuclei masks were then applied to the AF594 channel and 416 the threshold for AF594 staining was determined using stained mock-infected cells. Finally, 417 cells were considered infected if their AF594 signal was above this threshold. 42 fields were 418 scanned for each sample/condition to ensure the analysis of a sufficient number of cells. 419

HEK293T-ACE2 cells were seeded at a density 9 x 10 4 cells/well of an 8-well µ-Slide (Ibidi, 422 80826) in 250 µL complete media. After 1 h, cells were transfected in duplicate with the 423 indicated FlipGFP-based reporter constructs as above. The following morning, cells were 424 infected with SARS-CoV-2 at the indicated MOI and incubated for 24 h. 425

To measure reporter activation in infected cells using confocal microscopy, cells were first 426 Diagnostic cutoffs were determined by receiver operating characteristic (ROC) curve analysis. 518

Ethical approval for this study was granted by the East of England -Cambridge Central 520

Research Ethics Committee (08/H0308/176). Written informed consent was obtained from all 521 volunteers prior to providing serum samples. 522

A SARS-CoV-2 genomic alignment file was retrieved from the GISAID database 524 Fig 1B and Fig 1F- 

SARS-CoV-2 variants, spike mutations and immune escape

Feline 639 coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication

A comparative analysis 643 of remdesivir and other repurposed antivirals against SARS-CoV-2

Remdesivir and chloroquine 647 effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

BNT162b2 651 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Neutralising antibody 654 activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

Epigenetic silencing by the HUSH complex mediates position-effect 724 variegation in human cells

Lentivirus-728 delivered stable gene silencing by RNAi in primary cells

Neuropilin-1 is a host factor for SARS-CoV-2 infection

Methods of Inactivation of SARS-CoV-2 for Downstream Biological Assays

Amplicon-Based Detection and Sequencing of SARS-CoV-2 in Nasopharyngeal Swabs from

Patients With COVID-19 and Identification of Deletions in the Viral Genome That Encode

A 752 plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for

COVID-19 research

757 an open-source platform for biological-image analysis

Quantification 761 of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, 762 microneutralization and pseudotyped virus neutralization assays

Sequence logos: a new way to display consensus 778 sequences

A-B) Illustrative PRNT data from Fig 5A. SARS-CoV-2-ZsGreen viral stock